お知らせ

2018/01/08

Japan’s Prime Minister certified our business program as the first designated core project of the Tokyo Area zone in the National Strategic Special Zone.

Research and development of the manufacturing process of regenerative medical products utilizing Artificial Intelligence (AI) certified as the first designated core project of the Tokyo Area Zone in the National Strategic Special Zone, and Large funds procurement from venture capital investors



PharmaBio Corporation (hereinafter PharmaBio; Headquarters: Nagoya City, Aichi Prefecture; Representative Director: Hitoshi Kusano) is Japan's first private sector contract development and manufacturing organization (CDMO) specialized in cellular and tissue based products. In "Manufacturing of Regenerative Medical Products", it is necessary to produce high quality final products from heterogeneous raw materials such as living cells and tissues. By utilizing AI, we will perform a continuous tuning of the manufacturing process by feeding back analysis results of numerous combinations of manufacturing related parameters we acquired based on our years of experience and know-hows. This will enable us to contribute to the manufacturing of regenerative medical products.

After deliberations at the 32nd meeting of the Council in National Strategic Special Zone held on December 15, 2017, the initiative of PharmaBio is positioned to contribute to strengthening Japan's international competitiveness in the medical field . It has also been certified as the first designated core project of the Tokyo Area zone in the National Strategic Special Zone by the Prime Minister of Japan. (Outline of accredited project "Research and Development of the Manufacturing Process of Regenerative Medical Products with Stable Quality Using Original Analytical Methods Utilizing AI to Realize Curative Therapy of Diseases for Which Treatment Method Is Not Established")
http://www.kantei.go.jp/jp/singi/tiiki/kokusentoc/kuikikeikaku.html#tokyoken) 

Also, in promoting the CDMO business, PharmaBio has raised funds totaling 560 million Japanese yen with two Funds as underwriters. One of them is managed by The University of Tokyo Edge Capital Co., Ltd. (UTEC) (Hongo, Bunkyo, Tokyo, Managing Partner & President: Tomotaka Goji), another one is managed by TNP Sleds of Light Co., Ltd (Kohoku, Yokohama, Kanagawa, Representative Director: Masatoshi Go). This will enable rapid CDMO business development.


Difference in manufacturing process in types of raw materials.
- In manufacturing of Regenerative Medicine Products, efficiency can be improved by utilizing AI-



[About PharmaBio]
PharmaBio is the first private sector organization that specializes in contract development and manufacturing of Cellular and Tissue based Products (CDMO) in Japan. It provides safety-conscious support for development of Cellular and Tissue based Products. Its services include consultation on regulatory affairs, contract development and manufacturing of Cellular and Tissue based Products, and regulatory affairs solutions. These activities enable PharmaBio to provide services that are highly specialized and leverage the synergy between the areas of expertise. Its integrated service approach enables clients to materialize seamless and highly precise and efficient development processes in a single solution package. PharmaBio is also in a service alliance contract with Cell Therapies Pty Ltd. (Melbourne, Australis), which is known as a leading CDMO in the area of Cellular and Tissue based Products in the Asian Pacific region, and through which, is readily available to provide contract development and manufacturing services for global studies.

PharmaBio Corporation Administrative Department
Yuki Takahashi / hq_kanri@pharmabio.co.jp


To view a PDF version of this article please click here:

ご相談ください

ファーマバイオの製品やサービスおよび、開催予定の展示会やセミナーに関するご質問を承ります。お気軽にお問い合わせください。

電話:03-6205-4101
ファックス: 03-6205-4102
受付時間: 平日9:00~17:30